Vascular smooth muscle-specific knockdown of the noncardiac form of the L-type calcium channel by microRNA-based short hairpin RNA as a potential antihypertensive therapy

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 2, 2009, Pages 775-782

  Rhee, Sung W ^a   Stimers, Joseph R ^a   Wang, Wenze ^a   Pang, Li ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BARIUM; CALCIUM CHANNEL L TYPE; MICRORNA; MICRORNA 30A BASED SHORT HAIRPIN RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; L TYPE CALCIUM CHANNEL ALPHA(1C); L-TYPE CALCIUM CHANNEL ALPHA(1C);

ARTICLE; CELL CULTURE; CELL STRAIN; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA MODIFICATION; DRUG EFFECT; EMBRYO; ENHANCER REGION; GENE SILENCING; HEART MUSCLE CELL; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL MEMBRANE POTENTIAL; DOWN REGULATION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HYPERTENSION; METABOLISM; PATCH CLAMP; RNA INTERFERENCE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CALCIUM CHANNELS, L-TYPE; CELL LINE; DOWN-REGULATION; GENE THERAPY; HUMANS; HYPERTENSION; MEMBRANE POTENTIALS; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; PATCH-CLAMP TECHNIQUES; PLASMIDS; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 65649124497     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.148866     Document Type: Article

References (40)

1. Arnold AS, Tang YL, Qian K, Shen L, Valencia V, Phillips MI, and Zhang YC (2007) Specific betal-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. J Hy-pertens 25:197-205.
2. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, and Ramratnam B (2004) Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 32:1154-1158.
3. Burnier M (2006) Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 19:1190-1196.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252.
5. v1.2. Biochem Bio-phys Res Commun 296:429-433.
6. Eisenberg MJ, Brox A, and Bestawros AN (2004) Calcium channel blockers: an update. Am J Med 116:35-43.
7. Frishman WH (2007) Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 15:257-263.
8. Giering JC, Grimm D, Storm TA, and Kay MA (2008) Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16:1630-1636.
9. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, and Kay MA (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541.
10. Harrell MD and Stimers JR (2002) Differential effects of linoleic Acid metabolites on cardiac sodium current. J Pharmacol Exp Ther 303:347-355.
11. He J, Bian Y, Gao F, Li M, Qiu L, Wu W, Zhou H, Liu G, and Xiao C (2009) RNA interference targeting ACE gene reduced blood pressure and improved myocardial remodeling in SHR. Clin Sci (Lond) 116:249-255.
12. Hoggatt AM, Simon GM, and Herring BP (2002) Cell-specific regulatory modules control expression of genes in vascular and visceral smooth muscle tissues. Circ Res 91:1151-1159.
13. Koch WJ, Ellinor PT, and Schwartz A (1990) cDNA cloning of a dihydropyridine-sensitive calcium channel from rat aorta: evidence for the existence of alternatively spliced forms. J Biol Chem 265:17786-17791.
14. Lagos-Quint ana M, Rauhut R, Lendeckel W, and Tuschl T (2001) Identification of novel genes coding for small expressed RNAs.Science 294:853-858.
15. Ling X and Li F (2004) Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques 36:450-454, 456-460.
16. Liu YP, Haasnoot J, ter Brake O, Berkhout B, and Konstantinova P (2008) Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 36:2811-2824.
17. 2+ currents in small mesenteric artery myocytes from Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 29:1329-1336.
18. Moessler H, Mericskay M, Li Z, Nagl S, Paulin D, and Small JV (1996) The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development 122:2415-2425.
19. v1.2 for blood pressure regulation. EMBO J 22:6027-6034.
20. Ogorelkova M, Zwaagstra J, Elahi SM, Dias C, Guilbaut C, Lo R, Collins C, Jaramillo M, Mullick A, O'Connor-McCourt M, et al. (2006) Adenovirus-delivered antisense RNA and shRNA exhibit different silencing efficiencies for the endogenous transforming growth factor-beta (TGF-beta) type II receptor. Oligonucleotides 16:2-14.
21. 2+ channels in resistance arteries from spontaneously hypertensive rats. Circ Res 73:1090-1099.
22. v1.2 isoforms under the control of distinct 5′ flanking regulatory elements. FEBS Lett 546:349-354.
23. 2+ channels: is membrane depolarization the signal? Circ Res 94:e97-104.
24. Potera C (2007) Antisense-down, but not out. Nat Biotechnol 25:497-499.
25. 2+ channels in mesenteric and skeletal arteries of SHR. Hypertension 40:214-219.
26. Ribault S, Neuville P, Méchine-Neuville A, Augé F, Parlakian A, Gabbiani G, Paulin D, and Calenda V (2001) Chimeric smooth muscle-specific enhancer/promoters: valuable tools for adenovirus-mediated cardiovascular gene therapy. Circ Res 88:468-475.
27. v1.2 L-type calcium channel different from the principal heart form. Biochem Biophys Res Commun 302:23-28.
28. v1.2 transcripts in rat tissues mediated by different promoters. Cell Calcium 37:301-309.
29. Suva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, et al. (2005) Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37:1281-1288.
30. Solway J, Seltzer J, Samaha FF, Kim S, Alger LE, Niu Q, Morrisey EE, Ip HS, and Parmacek MS (1995) Structure and expression of a smooth muscle cell-specific gene, SM22 alpha. J Biol Chem 270:13460-13469.
31. Su J, Zhu Z, Xiong F, and Wang Y (2008) Hybrid cytomegalovirus-U6 promoter-based plasmid vectors improve efficiency of RNA interference in zebrafish. Mar Biotechnol (NY) 10:511-517.
32. Sun Z, Bello-Roufai M, and Wang X (2008) RNAi inhibition of mineralocorticoid receptors prevents the development of cold-induced hypertension. Am J Physiol Heart Circ Physiol 294:HI88O-HI887.
33. v1.2 channels with distinct biophysical properties. Cell Calcium 41:417-428.
34. Tanzer A and Stadler PF (2004) Molecular evolution of a microRNA cluster. J Mol Biol 339:327-335.
35. Triggle DJ (2003) 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell Mol Neurobiol 23:293-303.
36. v1.2 channels in spontaneously hypertensive rats. Am J Hypertens 19:823-831.
37. Wang X, Skelley L, Cade R, and Sun Z (2006b) AAV delivery of mineralocorticoid receptor shRNA prevents progression of cold-induced hypertension and attenuates renal damage. Gene Ther 13:1097-1103.
38. Xia H, Mao Q, Paulson HL, and Davidson BL (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006-1010.
39. Xia XG, Zhou H, and Xu Z (2006) Multiple shRNAs expressed by an inducible pol II promoter can knock down the expression of multiple target genes. Biotechniques 41:64-68.
40. Yuan J, Wang X, Zhang Y, Hu X, Deng X, Fei J, and Li N (2006) shRNA transcribed by RNA Pol II promoter induce RNA interference in mammalian cell. Mol Biol Rep 33:43-49.